Evidence map›Paper›PMID 35024844›Full record

ArticleThe Journal of infectious diseases2022

SARS-CoV-2 Placentitis Associated With B.1.617.2 (Delta) Variant and Fetal Distress or Demise.

Lydia L Shook, Sara Brigida, James Regan, James P Flynn, Abbas Mohammadi, Behzad Etemad, Molly R Siegel, Mark A Clapp, Jonathan Z Li, Drucilla J Roberts and 1 more

Abstract readCase Reports
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. SARS-CoV-2 immunity in animal models.Cellular & molecular immunology · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Lydia L ShookDepartment of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-5859-8610
Sara BrigidaVincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, Massachusetts, USA.
James ReganDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
James P FlynnDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abbas MohammadiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Behzad EtemadDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Molly R SiegelDepartment of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Mark A ClappDepartment of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jonathan Z LiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Drucilla J RobertsDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Andrea G EdlowDepartment of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-2915-5949

Funding

Harvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2M
Sex Differences in Fetal Brain-Placental Immune Programming in Maternal ObesityR01HD100022 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI EDLOW, ANDREA GOLDBERG · 2019 to 2021
$2.0M
Transdisciplinary Harvard WRHR Career Development for Gynecologists and ObstetriciansK12HD103096 · NICHD · BRIGHAM AND WOMEN'S HOSPITAL · PI NOUR, NAWAL M. · 2020 to 2024
$1.5M
NIAID NIH HHS UM1 AI069412NICHD NIH HHS K12 HD103096NICHD NIH HHS R01 HD100022
6 · The paper itself

Abstract

There is limited information on the specific impact of maternal infection with the SARS-CoV-2 B.1.617.2 (delta) variant on pregnancy outcomes. We present 2 cases of intrauterine fetal demise and 1 case of severe fetal distress in the setting of maternal infection with delta-variant SARS-CoV-2. In all cases, fetal demise or distress occurred within 14 days of COVID-19 diagnosis. Evaluation revealed maternal viremia, high nasopharyngeal viral load, evidence of placental infection with delta-variant SARS-CoV-2, and hallmark features of SARS-CoV-2 placentitis. We suggest that delta-variant SARS-CoV-2 infection during pregnancy warrants vigilance for placental dysfunction and fetal compromise regardless of disease severity.

Indexed as

Fetal DeathFetal DistressSARS-CoV-2AdultChorioamnionitisCOVID-19COVID-19 TestingFemaleHumansInfectious Disease Transmission, VerticalPlacentaPregnancyPregnancy Complications, InfectiousCOVID-19delta variantplacental infectionpregnancySARS-CoV-2 placentitisstillbirth

Identifiers

PMID35024844
PMCPMC8807229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.